Sodium-Glucose Transporter 2 Inhibitors: all 1,276 studies that test it
Page 3 of 13. Open to participants first (266), then studies with results posted, then the rest; newest registration first within each.
- Empagliflozin for Peripheral Microvascular Dysfunction in Heart Failure With Preserved Ejection FractionRecruitingNCT06046612Phase 4
- The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1RecruitingNCT06030843Phase 2/3
- Empagliflozin Treatment in Kidney Transplant RecipientsRecruitingNCT06013865Phase 4
- Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose RationaleNot yet recruitingNCT06012266Phase 2
- Clinical Investigation of the Cardioprotective Effect of Early Administration of SGLT2 in Patients Presented With AMIRecruitingNCT06009874Not applicable
- Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant TherapyRecruitingNCT05989347Phase 1
- Effect of Sodium-glucose Cotransporter-2 Inhibitor in Cellular Senescence in Patients With Cardiovascular Diseases or Type 2 DiabetesRecruitingNCT05975528Phase 4
- The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial FunctionRecruitingNCT05972564Phase 1/2
- SGLTi, Hepatic Glucose Production and KetogenesisRecruitingNCT05960656Phase 1
- Short and Intermediate Term Effect of Dapagliflozin on Left Ventricular Remodeling in Anterior STEMI PatientsRecruitingNCT05957887Phase 3
- Phase 3 Clinical Trial With Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult PatientsRecruitingNCT05944016Phase 3
- Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLDNot yet recruitingNCT05942963Phase 4
- The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant RecipientsRecruitingNCT05938712Phase 2
- Comparison of Dapagliflozin, Lobeglitazone, and Its Combination in Efficacy and SafetyRecruitingNCT05915949Phase 4
- Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic PatientsNot yet recruitingNCT05914857Phase 2
- Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatmentRecruitingNCT05905965Phase 3
- Canagliflozin With Gemcitabine in Pancreatic CarcinomaNot yet recruitingNCT05903703Not applicable
- Effect at 3 Months of Early Empagliflozin Initiation in Cardiogenic Shock Patients on Mortality, Rehospitalization, Left Ventricular Ejection Fraction and Renal Function.RecruitingNCT05879276Phase 3
- SGLT2 Inhibitor TrEatment iN Patients Awaiting cOronary arTery bYpass Surgery to Reduce Post-opErative AFRecruitingNCT05852704Phase 3
- Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Fibrosis (DEFORM)RecruitingNCT05848102Phase 4
- Dapagliflozin Evaluation on Atrial Fibrillation Patients Followed Cox Maze IV ProcedureRecruitingNCT05816733Phase 4
- To Evaluate the Effect of Food on the Safety and PK Characteristics of DWP16001 in Healthy Adult VolunteersRecruitingNCT05797922Phase 1
- Safety and Efficacy of Empagliflozin in HemodialysisRecruitingNCT05786443Phase 2
- Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart FailureRecruitingNCT05776043Phase 3
- DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial InfarctionRecruitingNCT05764057Phase 3
- Effect of Dapagliflozin on Microvascular Function in Women With Symptoms of Coronary Artery DiseaseRecruitingNCT05762952Phase 1
- To Compare the Safety and PK/PD Characteristics of Subjects With Between Hepatic Impairment and Normal Hepatic FunctionRecruitingNCT05747664Phase 1
- Empagliflozin in Patients With Cirrhosis and AscitesRecruitingNCT05726032Phase 2
- meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsisRecruitingNCT05715814Phase 3
- Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD StudyRecruitingNCT05713851Phase 2/3
- DApagliflozin Cardiovascular Effects on Patients at End-stage REnal DiseaseRecruitingNCT05685394Phase 4
- ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve ReplacementRecruitingNCT05672836Phase 4
- Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia PatientsRecruitingNCT05669742Phase 3
- Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLDRecruitingNCT05644717Phase 4
- Adipose Dysfunction, Imaging, Physiology, and Outcomes With Sodium Glucose Cotransporter 2 Inhibitor (SGLT2i) for Sleep Apnea: The ADIPOSA StudyRecruitingNCT05612594Phase 4
- Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative ColitisRecruitingNCT05610956Early Phase 1
- Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection FractionEnrolling by invitationNCT05600387Phase 4
- EMPAGUM: Effects of Empagliflozin on Gut Microbiota in Heart Failure With a Preserved Ejection FractionEnrolling by invitationNCT05584319Phase 4
- Dapagliflozin Effect in Cognitive Impairment in Stroke TrialRecruitingNCT05565976Phase 2/3
- Empagliflozin for New On-set Heart Failure Study Regardless of Ejection FractionRecruitingNCT05556044Phase 3
- Adipose Tissue Heterogeneity and Its Link to Type 2 DiabetesRecruitingNCT05501483Not applicable
- Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)RecruitingNCT05469659Phase 2
- A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes MellitusRecruitingNCT05466643Phase 3
- Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone PatientsNot yet recruitingNCT05443932Phase 4
- Canagliflozin Targeting Vascular InflammationRecruitingNCT05427084Phase 2/3
- Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart FailureRecruitingNCT05392764Phase 3
- PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesRecruitingNCT05390892Phase 4
- Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKDRecruitingNCT05359263Phase 2
- SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 DiabetesRecruitingNCT05345327Phase 3
- Sodium Glucose Co-Transporter 2 (SGLT2) and STEMIRecruitingNCT05305911Phase 2
- Comparison of the Effects of Dapagliflozin and Gemigliptin on Ketone Metabolism and Cardiac Remodeling in Type 2 DiabetesRecruitingNCT05194592Phase 4
- Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)RecruitingNCT05174052Phase 3
- Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE StudyRecruitingNCT05164263Phase 4
- Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2DNot yet recruitingNCT05140694Phase 4
- SGLT2i and KNO3 in HFpEF - The SAK HFpEF TrialRecruitingNCT05138575Phase 2
- SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research PlanRecruitingNCT05057806Early Phase 1
- Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary InterventionRecruitingNCT04899479Phase 4
- Association Between Dapagliflozin-induced Improvement and Anemia in Heart Failure Patients (ADIDAS)RecruitingNCT04707261Phase 4
- Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.RecruitingNCT04662723Phase 4
- Ertugliflozin in Chronic Heart FailureRecruitingNCT04438213Phase 2
- Randomised Evaluation of COVID-19 TherapyRecruitingNCT04381936Phase 3
- Asian Diabetes Outcomes Prevention TrialRecruitingNCT04286399Phase 4
- DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular RiskRecruitingNCT04258371Phase 2
- SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver DiseaseNot yet recruitingNCT03867487Phase 2
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingNCT03424005Phase 1/2
- Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)RecruitingNCT02969798Not applicable
- Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney DiseaseCompletedNCT06435858Phase 2Results posted
- A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCKCompletedNCT06269484Phase 2Results posted
- Anti-Diabetic Medications to Fight PD and LBDCompletedNCT06263673Phase 4Results posted
- SGLT2 Inhibitor Therapy in Cystic Fibrosis-related DiabetesActive, not recruitingNCT06149793Phase 2/3Results posted
- Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis PatientsCompletedNCT05748925Phase 4Results posted
- DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN StudyCompletedNCT05727579Phase 4Results posted
- Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) PatientsCompletedNCT05562063Phase 4Results posted
- Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)TerminatedNCT05516498Phase 2Results posted
- The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart FailureTerminatedNCT05346653Phase 4Results posted
- A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)TerminatedNCT05282121Phase 2Results posted
- HF Patients With LVADs Being Treated With SGLT2iCompletedNCT05278962Phase 4Results posted
- A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 DiabetesCompletedNCT05254002Phase 2Results posted
- SGLT2 Inhibitors in Transthyretin Amyloid CardiomyopathyCompletedNCT05233163Phase 4Results posted
- Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes MellitusCompletedNCT05232071Phase 2Results posted
- A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney DiseaseCompletedNCT05182840Phase 2Results posted
- Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 DiabetesTerminatedNCT05139914Phase 4Results posted
- A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered TogetherCompletedNCT05083949Phase 1Results posted
- SNIFF - Combo INI+EMPA TrialCompletedNCT05081219Phase 2Results posted
- Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant RecipientsCompletedNCT04965935Phase 3Results posted
- SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity PilotCompletedNCT04907214Phase 1/2Results posted
- Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and FulvestrantTerminatedNCT04899349Phase 2Results posted
- The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary StudyCompletedNCT04818034Phase 2Results posted
- Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial FibrillationCompletedNCT04792190Phase 4Results posted
- Dapagliflozin (DAPA) Effects in HFpEFCompletedNCT04730947Phase 2Results posted
- Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III StudyTerminatedNCT04600921Phase 3Results posted
- Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.CompletedNCT04564742Phase 3Results posted
- Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) InhibitionCompletedNCT04542291Phase 1Results posted
- A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 YearsCompletedNCT04531462Phase 4Results posted
- EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)CompletedNCT04509674Phase 3Results posted
- To Assess Safety of Fixed Dose Combination of Dapagliflozin and Saxagliptin in Type 2 Diabetes Mellitus PatientsCompletedNCT04445714Phase 4Results posted
- SGLT2 Inhibition in Older Obese Adults With Pre-diabetesCompletedNCT04401904Phase 1/2Results posted
- Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)CompletedNCT04363697Phase 4Results posted
- Dapagliflozin in Respiratory Failure in Patients With COVID-19CompletedNCT04350593Phase 3Results posted
- The Effect of empagliFlozin on Platelet Function profilEs in diabetiC patienTs - The EFFECT Study.CompletedNCT04342819Phase 2/3Results posted